Microneedle-Based Natural Polysaccharide for Drug Delivery Systems (DDS): Progress and Challenges.
Fouad DamiriNagavendra KommineniSamuel Ogbeide EbhodagheRaviteja BulusuVaskuri G S Sainaga JyothiAmany A SayedAeshah A AwajiMousa O GermoushHamdan S Al-MalkyMohammed Zahid NasrullahMd Habibur RahmanMohamed M Abdel-DaimMohammed BerradaPublished in: Pharmaceuticals (Basel, Switzerland) (2022)
In this focused progress review, the most widely accepted methods of transdermal drug delivery are hypodermic needles, transdermal patches and topical creams. However, microneedles (MNs) (or microneedle arrays) are low-invasive 3D biomedical constructs that bypass the skin barrier and produce systemic and localized pharmacological effects. In the past, biomaterials such as carbohydrates, due to their physicochemical properties, have been extensively used to manufacture microneedles (MNs). Due to their wide range of functional groups, carbohydrates enable the design and development of tunable properties and functionalities. In recent years, numerous microneedle products have emerged on the market, although much research needs to be undertaken to overcome the various challenges before the successful introduction of microneedles into the market. As a result, carbohydrate-based microarrays have a high potential to achieve a future step in sensing, drug delivery, and biologics restitution. In this review, a comprehensive overview of carbohydrates such as hyaluronic acid, chitin, chitosan, chondroitin sulfate, cellulose and starch is discussed systematically. It also discusses the various drug delivery strategies and mechanical properties of biomaterial-based MNs, the progress made so far in the clinical translation of carbohydrate-based MNs, and the promotional opportunities for their commercialization. In conclusion, the article summarizes the future perspectives of carbohydrate-based MNs, which are considered as the new class of topical drug delivery systems.